Velocity Pharmaceutical Development

Velocity Pharmaceutical Development acquires rights to individual therapeutic drug candidates from biotech and pharma companies and invests in their development through clinical proof-of-concept. The company specializes in both small molecule and biologic drugs that are underserved or overlooked by larger firms. Its model involves creating project-focused companies for each candidate, advancing them rapidly to key value inflection points such as Phase 1 trials. The company has participated in notable partnerships such as the formation of Vitesse Biologics with Baxalta and Mayo Clinic, targeting hematology, oncology, and immunology indications. Specific pipeline details are not publicly disclosed.